Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Xeris Biopharma Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Xeris Biopharma Holdings's regulatory disclosures and financial reporting.
Xeris Biopharma Holdings, Inc. files its annual report describing a commercial-stage biopharma business focused on chronic endocrine and neurological diseases in the United States. As of June 30, 2025, non‑affiliate common stock had an aggregate market value of about $731.1 million, and 172,431,290 shares were outstanding as of February 27, 2026.
The company markets three main products: Recorlev for Cushing’s syndrome, which it believes can reach about $1 billion in peak annual U.S. net revenue; Gvoke, a ready‑to‑use glucagon for severe hypoglycemia with an estimated $5.0 billion U.S. addressable market; and Keveyis for primary periodic paralysis with a U.S. market potential above $0.5 billion.
Xeris highlights its lead pipeline candidate XP‑8121, a once‑weekly subcutaneous levothyroxine using its proprietary XeriSol technology, targeting a hypothyroidism peak sales opportunity of $1.0 to $3.0 billion in the United States. The report also emphasizes the company’s XeriSol and XeriJect formulation platforms, extensive global patent estate, reliance on third‑party manufacturers, and detailed U.S. regulatory, intellectual property, and compliance frameworks governing its products and development programs.
Xeris Biopharma reported record results for the fourth quarter and full year 2025 and issued strong 2026 guidance. Fourth quarter total revenue rose to $85.8 million from $60.1 million, driven by Recorlev, Gvoke and Keveyis growth, and net income reached $11.1 million versus a prior-year net loss of $5.1 million.
For 2025, total revenue increased to $291.8 million from $203.1 million, with Recorlev sales more than doubling. The company generated full-year net income of $0.6 million, a sharp improvement from a $54.8 million loss in 2024. Adjusted EBITDA improved to $59.4 million from $1.2 million, reflecting higher sales and operating leverage.
For 2026, Xeris expects total revenue between $375 million and $390 million, implying more than 30% growth at the midpoint, and projects higher R&D and SG&A to support XP-8121 Phase 3 development and Recorlev investment while increasing Adjusted EBITDA versus 2025.
Xeris Biopharma Holdings, Inc. officer Anh Tu Nguyen reported a Form 4 transaction where 29,300 shares of common stock were withheld by the company at $6.88 per share to cover income tax obligations on vested restricted stock units as of February 24, 2026.
After this tax-withholding disposition, Nguyen directly owned 395,023 shares of common stock, with additional indirect holdings of 3,710 shares through an IRA and 3,501 shares through children’s IRAs, for which he disclaims full beneficial ownership beyond his pecuniary interest.
Xeris Biopharma Holdings, Inc. director and Chief Executive Officer Shannon John Patrick Jr reported equity compensation and related tax-withholding activity in company stock. On January 30, 2026, he received 478,436 shares of common stock for $0, issued as restricted stock units that vest in equal annual installments over three years, subject to continued employment. On the same date, he was granted 639,639 stock options with a $7.36 exercise price, also vesting in equal annual installments over three years and expiring on January 30, 2036. On January 31, 2026, the company withheld blocks of common shares at $7.36 per share to cover income tax and withholding obligations tied to vested restricted stock units. After these transactions, he directly owned 2,935,578 shares of common stock and 639,639 stock options.
Xeris Biopharma Holdings, Inc. executive equity activity: President and Chief Operating Officer Kevin McCulloch reported new stock-based compensation and related tax share withholdings. On January 30, 2026, he received 168,463 shares of common stock through a restricted stock unit grant that vests in three equal annual installments, subject to continued employment.
On the same date, he was granted 225,225 stock options with a $7.36 exercise price, also vesting in three equal annual installments, subject to continued service. On January 31, 2026, the company withheld 68,454, 30,289, and 27,319 shares at $7.36 per share to cover income tax obligations on vested restricted stock units. After these transactions, he directly owned 1,727,827 common shares.
The filing also notes 25,000 shares held indirectly by his spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings reported insider equity awards and related tax share withholding for Chief Financial Officer Steven Pieper. On January 30, 2026, he received 154,986 shares of common stock through a restricted stock unit grant under the 2018 Stock Option and Incentive Plan, vesting in equal annual installments over three years, subject to continued employment.
On the same date, he was granted 207,207 stock options with an exercise price of $7.36 per share, also vesting annually over three years and expiring on January 30, 2036. On January 31, 2026, a total of 206,?
Xeris Biopharma Holdings Chief Medical Officer Nguyen Anh Tu reported new equity awards. On January 30, 2026, he received 121,293 shares of common stock through a restricted stock unit grant and 162,162 stock options with a $7.36 exercise price.
The restricted stock units and stock options each vest in equal annual installments over three years, conditioned on continued employment or service. Following the grant, he directly holds 424,323 shares of common stock and 162,162 options, plus indirect holdings of common stock through an IRA and a children's IRA, for which he disclaims beneficial ownership beyond his economic interest.
Xeris Biopharma Holdings’ Chief Legal Officer and Corporate Secretary Beth Hecht reported multiple equity transactions in XERS stock. On January 30, 2026, she received 121,293 shares of common stock via restricted stock units and a grant of 162,162 stock options under the company’s 2018 Stock Option and Incentive Plan, both vesting in equal annual installments over three years.
On January 31, 2026, a total of shares were withheld at $7.36 per share to cover taxes on vested restricted stock units. On February 2, 2026, she sold 16,667 shares of common stock at a weighted average price of $7.4487 per share pursuant to a pre-arranged Rule 10b5-1 trading plan, leaving her with 1,243,174 shares of directly owned common stock.
The Vanguard Group has filed an amended Schedule 13G reporting beneficial ownership of Xeris Biopharma Holdings Inc common stock. Vanguard reports beneficial ownership of 11,186,677 shares, representing 6.74% of the outstanding common stock as of the triggering date.
Vanguard reports no sole voting or dispositive power, with shared voting power over 1,339,227 shares and shared dispositive power over 11,186,677 shares. The filing explains that Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds, and that no single client holds more than 5% of the class. Vanguard states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Xeris Biopharma. The filing also notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries may report beneficial ownership on a disaggregated basis.